Horizon Discovery产品代理
Horizon Discovery产品代理
业务部门
Horizon目前通过四个业务部门运营
研究试剂：提供工具和服务，帮助科学家更好地了解疾病的生物学途径和机制，以及用于开发诊断测试的分子参考标准
筛选和细胞系工程服务：提供旨在改善药物发现和开发结果的工具和服务
BioProduction 细胞系：提供工程 CHO 细胞系，旨在实现高效的生物制剂生产
基础编辑：开发基于高度准确、新颖的平台的工具和服务，Horizon打算授权其客户进行基因和细胞治疗开发。碱基编辑是基因编辑中的一个新类别，它允许科学家对 DNA 中的单个碱基进行特定编辑，目的是通过减少意外的基因组变化来提供更准确的基因编辑。作为一项新技术，碱基编辑尚未经过临床验证可用于人类治疗。
文件夹
Horizon的业务以细胞工程工具和服务组合为基础，包括 CRISPR 等基因编辑技术和 RNAi 等碱基编辑和基因调制技术。
Horizon的产品支持并支持药物开发和治疗价值链的关键要素，尤其是在精准医疗领域。
全球范围
Horizon的客户包括全球的生物制药和诊断公司、合同研究和制造组织以及学术研究人员。 Horizon向 60 多个国家/地区的 2,000 多个独特客户销售其工具和服务，其中包括按收入计算的 20 家最大的生物制药公司中的 19 家。
Horizon is leveraging its technological expertise to provide cell engineering tools and services to its customers in three key areas of the therapeutic ecosystem: basic research, drug discovery and development and therapeutic applications.
Business units
Horizon currently operates through four business units
Research reagents: offers tools and services that help scientists better understand biological pathways and mechanisms of disease, as well as molecular reference standards used in the development of diagnostics tests
Screening & Cell line engineering services: offers tools and services that are designed to improve the outcome of drug discovery and development
BioProduction cell lines: offers engineered CHO cell lines that are designed to enable efficient biologics manufacturing
Base editing: develops tools and services that are based on a
highly accurate, novel platform that Horizon intends to license to its customers for gene and cell therapeutic development. Base editing is a new category in gene editing that allows scientists to make specific edits to single bases in DNA, with the goal of providing more accurate gene editing by reducing unintended genomic changes. As a novel technology, base editing has not yet been clinically validated for use in human therapeutics.
Portfolio
Horizon’s business is underpinned by its portfolio of cell engineering tools and services, featuring gene editing technologies such as CRISPR and base editing and gene modulation technologies such as RNAi. Horizon’s offerings support and enable critical elements of the drug development and therapeutic value chain, particularly in the area of precision medicine.
Global reach
Horizon’s customers include biopharmaceutical and diagnostics companies, contract research and manufacturing organizations and academic researchers across the globe. Horizon sells its tools and services to more than 2,000 unique customers in over 60 countries, including to 19 of the 20 largest biopharmaceutical companies by revenue.
